Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Lilly Gets Windfall From Amylin Sale
by Lisa M. Jarvis
August 20, 2012
| A version of this story appeared in
Volume 90, Issue 34
Eli Lilly & Co. is the recipient of a nearly $1.3 billion windfall following Bristol-Myers Squibb’s acquisition of the diabetes drug firm Amylin. In November, Lilly and Amylin ended their decade-long partnership for developing exenatide, a GLP-1 receptor agonist for the treatment of type 2 diabetes sold under the brand name Byetta. Under the terms of their breakup, Amylin was to pay Lilly as much as 15% of sales of Byetta up to $1.2 billion. Amylin opted to make the payment early, plus pay back a $165 million loan from Lilly. Lilly says the cash influx will be used to advance its business and its drug pipeline.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter